

TECHNICAL MANUAL

Maintenance of Human Pluripotent Stem Cells in TeSR™-E8™

Critical Parameters for Successful Cell Culture with TeSR™-E8™

Preparation and Storage of Complete TeSR™-E8™

It is critical to store complete TeSR™-E8™ in either the TeSR™-E8™ Basal Medium bottle or 50 mL polypropylene tubes (e.g. Catalog #38010) for optimal performance. Do not use other containers. For instructions on how to prepare complete TeSR™-E8™ medium, see section 4.1.

Choosing an Appropriate Matrix for Use With TeSR™-E8™

Cells may be cultured in TeSR™-E8™ using either Vitronectin XF™ or Corning® Matrigel® as the surface coating matrix. Corning® Matrigel® is a routinely used surface coating matrix for a variety of applications, although the composition is undefined. In contrast, Vitronectin XF™ consists of a single humanized protein matrix that is fully defined. Vitronectin XF™ is recommended for applications where a fully defined culture system is desired. For coating cultureware with these matrices, see section 4.2.

Choosing an Appropriate Passaging Reagent for Use With TeSR™-E8™

Cells cultured in TeSR™-E8™ can be passaged using the enzyme-free passaging reagents ReLeSR™ (section 5.1) or Gentle Cell Dissociation Reagent (section 5.2). Passaging protocols using enzymatic reagents (e.g. Dispase) should not be used when passaging cells cultured in TeSR™-E8™.

Among the enzyme-free passaging reagents, ReLeSR™ allows the quickest and most straightforward protocol for routine passaging of human ES and iPS cells as cell aggregates. Unlike passaging using Gentle Cell Dissociation Reagent, passaging with ReLeSR™ does not require manual selection of differentiated areas or scraping to remove cell aggregates. With any passaging protocol, ensure that you have optimized the exposure time to the passaging reagent used; the appearance of colonies after dissociation should be as shown in Figure 9 (ReLeSR™) or Figures 10 & 11 (Gentle Cell Dissociation Reagent). The incubation time may vary when using different cell lines or other cell passaging reagents; dissociation should be monitored under the microscope until the optimal time is determined. Avoid overexposure, which leads to the generation of single cells. If single cells are generated, refer to section 8.0 for troubleshooting suggestions.

Aggregate vs. Single-Cell Passaging

The protocols in this manual for the routine expansion of human ES and iPS cells are for passaging of cells as small aggregates of approximately 50 - 200 µm in diameter. These established methods have been shown to allow the long-term expansion of many different cell lines while maintaining a normal karyotype. It is possible to passage human ES and iPS cells as single cells; however, it has been demonstrated that this practice can place unwanted selective pressure on cell populations and could lead to genetic aberrations in the culture.^{1,2} Therefore, if you perform single-cell passaging of human ES or iPS cells in any culture medium, check the karyotype frequently to ensure that the culture has retained a normal karyotype.

Characterization of Human ES and iPS Cells

It is good practice to monitor your cultures frequently to ensure maintenance of undifferentiated cells and a normal karyotype. Flow cytometry protocols for assessing the proportion of undifferentiated cells are described in Appendix 2. Human ES and iPS cells should retain a normal genetic makeup during routine culture, expansion, and manipulation. Nonetheless, chromosomal and genetic aberrations may appear during long-term passaging.¹⁻³ Accordingly, it is important to periodically (approximately every 10 - 20 passages) check human ES and iPS cell cultures to exclude the possibility of an abnormal karyotype. More frequent screening for recurrent abnormalities commonly associated with ES/iPS cell culture can be performed using tools such as the hPSC Genetic Analysis Kit (Catalog #07550).

Colony Density of Human ES and iPS Cell Cultures

Maintaining a proper colony density is a critical aspect of maintaining human ES and iPS cells in TeSR™-E8™. A range of colony densities can be tolerated in TeSR™-E8™, as shown in Figure 13; it is recommended to adjust plating density to maintain the culture at the desired confluence (i.e. increase/decrease split ratio). By altering this parameter, the optimal day of passage may be influenced (section 6.0 and Appendix 1). Some cell lines may show increased spontaneous differentiation when cultured at higher densities; if increased differentiation is observed, the colony density may be decreased in the next passage by plating fewer cell aggregates.

Transitioning Cells Cultured in Other Feeder-free Media to TeSR™-E8™

Human ES and iPS cells cultured in mTeSR™ 1, mTeSR™ Plus, TeSR™ 2, or other feeder-free media can be conveniently transferred to TeSR™-E8™ (section 7.1.1). Cells should transition smoothly into TeSR™-E8™ with minimal differences in morphology, pluripotency, or growth rate.

Transitioning Cells Cultured on a Feeder Layer to TeSR™-E8™

Human ES and iPS cells cultured on a layer of feeder cells can be conveniently transferred to TeSR™-E8™ (section 7.1.4). Cells should adapt to feeder-free culture within 1 - 2 passages and thereafter exhibit morphology consistent with feeder-free human pluripotent stem cells.

Table of Contents

Critical Parameters for Successful Cell Culture with TeSR™-E8™	i
1.0 Introduction	1
2.0 Materials, Reagents, and Equipment	2
2.1 TeSR™-E8™ (Catalog #05990)	2
2.2 Additional Materials for Human ES and iPS Cell Culture	2
2.3 Equipment Required for Human ES and iPS Cell Culture	3
3.0 Culturing Human ES and iPS Cells Using TeSR™-E8™	4
3.1 Morphology of Cells Cultured in TeSR™-E8™	4
3.2 Assessing TeSR™-E8™ Cultures to Determine Day of Passage	6
4.0 Preparation of Reagents and Materials	15
4.1 Complete TeSR™-E8™ Medium	15
4.2 Matrices for Coating Cultureware	15
4.2.1 Corning® Matrigel®	16
4.2.2 Vitronectin XF™	16
5.0 Enzyme-Free Passaging of Human ES and iPS Cells Cultured in TeSR™-E8™	18
5.1 ReLeSR™	18
5.2 Gentle Cell Dissociation Reagent (GCDR)	19
6.0 Customizing the Passaging Protocol	23
6.1 Cell Aggregate Size	24
6.2 Colony Density at Time of Passaging	25
7.0 Additional Protocols	26
7.1 Transitioning Cells	26
7.1.1 From Feeder-Free Media to TeSR™-E8™	26
7.1.2 From TeSR™-E8™ to mTeSR™ 1, mTeSR™ Plus, or TeSR™ 2	26
7.1.3 Cultured on Corning® Matrigel® to Vitronectin XF™	26
7.1.4 Cultured on a Feeder Layer to TeSR™-E8™	27
7.2 Preparing a Single-Cell Suspension for Downstream Applications	28
7.3 Cryopreserving and Thawing Cells	29
7.3.1 CryoStor® CS10 (Cell Aggregates)	29
7.3.2 FreSR™-S (Single Cells)	31

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

8.0	Troubleshooting	33
9.0	References	34
Appendix 1: Plating Human ES and iPS Cells Using the Cell Aggregate Count Method.....		35
Appendix 2: Flow Cytometry Protocols		36
	Reagents and Materials	36
	Preparation of a Single-Cell Suspension for Flow Cytometry	37
	Surface Antigen Labeling Protocol	37
	Intracellular Antigen Labeling Protocol for OCT3/OCT4	38

1.0 Introduction

The maintenance and expansion of human pluripotent stem cells (embryonic stem [ES] cells and human induced pluripotent stem [iPS] cells) in feeder-free conditions requires the use of complex media formulations, in combination with careful handling techniques, to maintain high-quality cultures at each passage. Recent efforts have focused on improving the general utility and reproducibility of human ES and iPS cell culture protocols by developing new and more straightforward strategies that increase consistency by the removal of undefined or unnecessary components from the culture system. A simplified version of the commercially available mTeSR™ 1 and TeSR™ 2 human ES and iPS cell maintenance media, referred to as E8™, has been reported by Dr. James Thomson's lab.⁴⁻⁷ E8™ was developed via the pairwise removal of extraneous additives from the TeSR™ core medium formulation, resulting in an albumin-free medium with a minimum set of components.

TeSR™-E8™ is a low-protein, feeder-free maintenance medium for human ES and iPS cells that is based on the published E8™ formulation. When combined with the protocols described in this manual, TeSR™-E8™ is capable of maintaining high-quality human ES and iPS cells similar to those cultured in mTeSR™ 1, mTeSR™ Plus, and TeSR™ 2. This medium may be used with Corning® Matrigel®, or alternatively with Vitronectin XF™ (developed and manufactured by Nucleus Biologics) recombinant protein matrix if a fully defined culture system is desired.

2.0 Materials, Reagents, and Equipment

2.1 TeSR™-E8™ (Catalog #05990)

COMPONENT NAME	COMPONENT #	SIZE	STORAGE	SHELF LIFE
TeSR™-E8™ Basal Medium	05991	480 mL	Store at 2 - 8 °C.	Stable for 12 months from date of manufacture (MFG) on label.
TeSR™-E8™ 25X Supplement	05992	20 mL	Store at -20°C.	Stable for 2 years from date of manufacture (MFG) on label.

2.2 Additional Materials for Human ES and iPS Cell Culture

CATEGORY	PRODUCT	CATALOG #
Culture Media	mTeSR™1	85850
	mTeSR™ Plus	05825
	TeSR™2	05860
Passaging Reagents	ReLeSR™	05872
	Gentle Cell Dissociation Reagent	07174
Matrices and Related Materials	Vitronectin XF™	07180
	Vitronectin XF™ Kit with GCDR	07190
	Vitronectin XF™ Kit with ReLeSR™	07191
	CellAdhere™ Dilution Buffer	07183
	Non-tissue culture-treated 6-well plates*	e.g. 27147 or 38040
	Corning® Matrigel® hESC-Qualified Matrix	Corning 354277
	Tissue culture-treated cultureware**	e.g. 38016 (6-well plates)
Cryopreservation Media	CryoStor® CS10	07930
	FreSR™-S	05859
Other Materials	DMEM/F-12 with 15 mM HEPES	36254
	Cell scrapers	e.g. 38065
	15 mL conical tubes	e.g. 38009
	D-PBS (Without Ca++ and Mg++)	37350
	Y-27632 (ROCK inhibitor)	72302
	Trypan Blue	07050
	CloneR™	05888
	hPSC Genetic Analysis Kit	07550

*Required for use with Vitronectin XF™.

**Required for use with Corning® Matrigel®.

For a complete list of products for human ES and iPS cell research available from STEMCELL Technologies Inc., visit www.stemcell.com.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

2.3 Equipment Required for Human ES and iPS Cell Culture

- Biohazard safety cabinet certified for Level II handling of biological materials
- Incubator with humidity and gas control to maintain 37°C and 95% humidity in an atmosphere of 5% CO₂ in air
- Low-speed centrifuge with a swinging bucket rotor
Note: All centrifugation protocols described in this manual can be performed with the brake on.
- Pipette-Aid with appropriate serological pipettes
- Pipettor (e.g. Catalog #38058) with appropriate tips
- Inverted microscope with a total magnification of 20X to 100X
- Isopropanol freezing container (e.g. Fisher Catalog #1535050)
- -150°C freezer or liquid nitrogen (LN₂) vapor tank
- -80°C freezer
- -20°C freezer
- Refrigerator (2 - 8°C)

3.0 Culturing Human ES and iPS Cells Using TeSR™-E8™

Culture of human ES and iPS cells in TeSR™-E8™ may require different techniques than culture in other media. The procedures described in this manual are general and may require optimization for use with specific cell lines.

3.1 Morphology of Cells Cultured in TeSR™-E8™

Undifferentiated human ES cells (Figure 1A and Figure 2A) and iPS cells (Figure 3A and Figure 4A) cultured in TeSR™-E8™ grow as compact, multicellular colonies characterized by distinct borders. The individual cells should be tightly packed, exhibit a high nuclear-to-cytoplasm ratio, and have prominent nucleoli. Healthy colonies will merge together seamlessly, and will be multi-layered in the center, resulting in dense clusters of cells when viewed under phase contrast. Colonies cultured in TeSR™-E8™ have a more condensed and round morphology when cultured on Vitronectin XF™ (Figure 1 and Figure 3) compared to colonies cultured on Corning® Matrigel® (Figure 2 and Figure 4), which are more diffuse and irregularly shaped. On both matrices, spontaneous differentiation is characterized by loss of colony border integrity, regions of irregular cell morphology within a colony, and/or the emergence of alternate cell types (Figure 1B, Figure 2B, Figure 3B, and Figure 4B).




Figure 1. Morphology of Human ES Cells Cultured on Vitronectin XF™ in TeSR™-E8™

(A) Undifferentiated human ES cells (H1 and H9) at the optimal time of passaging. (B) Area of spontaneous differentiation (orange outline) at the border of an undifferentiated H1 colony. Magnifications: 20X, 40X, and 400X.




Figure 2. Morphology of Human ES Cells Cultured on Corning® Matrigel® in TeSR™-E8™

(A) Undifferentiated human ES cells (H1 and H9) at the optimal time of passaging. (B) Area of spontaneous differentiation (orange circle) between undifferentiated H1 colonies. Magnifications: 20X, 40X, and 400X.




Figure 3. Morphology of Human iPS Cells Cultured on Vitronectin XF™ in TeSR™-E8™

(A) Undifferentiated human iPS cells (A13700 and WLS-1C) at the optimal time of passaging. (B) Area of spontaneous differentiation (orange circle) within an undifferentiated WLS-1C colony. Magnifications: 20X, 40X, and 400X.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.





Figure 4. Morphology of Human iPS Cells Cultured on Corning® Matrigel® in TeSR™-E8™

(A) Undifferentiated human iPS cells (A13700 and WLS-1C) at the optimal time of passaging. (B) Areas of spontaneous differentiation (orange circles) between undifferentiated A13700 colonies. Magnifications: 20X, 40X, and 400X.

3.2 Assessing TeSR™-E8™ Cultures to Determine Day of Passage

Human ES and iPS cells cultured in TeSR™-E8™ are ready to passage when the majority of colonies are large, compact, and have centers that are dense compared to their edges (Figures 5 - 8). It is to be expected that colony morphology will look different when compared to cells grown using other culture conditions. For up to 4 days after plating in TeSR™-E8™, colonies may not be very densely packed with cells. The density and robustness of the colonies increases rapidly after this timepoint and the morphology changes significantly in the last 1 - 2 days before passaging.

If colonies are passaged too early or too frequently, the cell aggregates may not attach well when replated, yields will be decreased, and cells may start to differentiate (characterized by the emergence of cell types with different morphologies). If colonies are passaged too late, the culture may begin to show signs of differentiation. There is an approximate 24- to 48-hour window that is optimal for passaging. If there are large colonies with dense centers, passage the cells within 24 hours (for further help, see section 8.0).



PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.





Figure 5. Human ES Cells Cultured on Vitronectin XF™ in TeSR™-E8™ at Days 1 - 7 After Passaging
Human ES cells (H1) at a magnification of (A) 20X and (B) 40X. For this culture, Day 6 or 7 would be the optimal window for passaging. The optimal day of passage for each culture will depend on plating density (section 6.2) and aggregate size used (section 6.1).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.



PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.





Figure 6. Human ES Cells Cultured on Corning® Matrigel® in TeSR™-E8™ at Days 1 - 7 After Passaging
Human ES cells (H1) at a magnification of (A) 20X and (B) 40X. For this culture, Day 5 or 6 would be the optimal window for passaging. The optimal day of passage for each culture will depend on plating density (section 6.2) and aggregate size used (section 6.1).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.



PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.





Figure 7. Human iPS Cells Cultured on Vitronectin XF™ in TeSR™-E8™ at Days 1 - 7 After Passaging
Human iPS cells (WLS-1C) at a magnification of (A) 20X and (B) 40X. For this culture, Day 6 or 7 would be the optimal window for passaging. The optimal day of passage for each culture will depend on plating density (section 6.2) and aggregate size used (section 6.1).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.



PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.




Figure 8. Human iPS Cells Cultured on Corning® Matrigel® in TeSR™-E8™ at Days 1 - 7 After Passaging
Human iPS cells (A13700) at a magnification of (A) 20X and (B) 40X. For this culture, Day 6 would be the optimal time for passaging. The optimal day of passage for each culture will depend on plating density (section 6.2) and aggregate size used (section 6.1).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

4.0 Preparation of Reagents and Materials

4.1 Complete TeSR™-E8™ Medium

Use sterile techniques to prepare complete TeSR™-E8™ medium (Basal Medium + 25X Supplement). The following example is for preparing 500 mL of complete medium. If preparing other volumes, adjust accordingly.

Note: Thaw supplements or complete medium at room temperature (15 - 25°C) or overnight at 2 - 8°C.

Do not thaw in a 37°C water bath.

1. Thaw TeSR™-E8™ 25X Supplement at room temperature (15 - 25°C) or overnight at 2 - 8°C. Mix thoroughly.

Note: Once thawed, use supplement immediately. Do not re-freeze.

2. Add (pipette) 20 mL of TeSR™-E8™ 25X Supplement to 480 mL of TeSR™-E8™ Basal Medium. Mix thoroughly.

Note: If not used immediately, store complete TeSR™-E8™ medium in one of the following containers:

- TeSR™-E8™ Basal Medium bottle
- 50 mL polypropylene tubes (e.g. Catalog #38010)

Do not use other storage containers.

3. Store complete medium at 2 - 8°C for up to 2 weeks. Alternatively, aliquot and store at -20°C for up to 6 months. Do not exceed the shelf life of the individual components. After thawing the aliquoted complete medium, use immediately or store at 2 - 8°C for up to 2 weeks. Do not re-freeze.

Note: Thaw complete medium at room temperature (15 - 25°C) or overnight at 2 - 8°C. Do not thaw in a 37°C water bath.

If prepared aseptically, complete TeSR™-E8™ medium is ready for use and does not require filtering.

4.2 Matrices for Coating Cultureware

Successful culture of human ES and iPS cells in TeSR™-E8™ requires the use of a suitable matrix to allow attachment of cell aggregates. Vitronectin XF™ or Corning® Matrigel® hESC-Qualified Matrix are recommended for use with TeSR™-E8™. Vitronectin XF™ recombinant protein matrix is recommended if a fully defined culture system is desired.

Use sterile technique when coating cultureware. For specific instructions for each matrix, refer to section 4.2.1 (Corning® Matrigel®) or 4.2.1 (Vitronectin XF™). Refer to Table 1 for recommended volumes of diluted matrix for coating various cultureware.

Table 1. Recommended Volumes for Coating Cultureware

CULTUREWARE*	VOLUME OF DILUTED MATRIX
6-well plate	1 mL/well
100 mm dish	6 mL/dish
T-25 cm ² flask	3 mL/flask
T-75 cm ² flask	8 mL/flask

*Non-tissue culture-treated cultureware is required for use with Vitronectin XF™.

4.2.1 Corning® Matrigel®

Corning® Matrigel® hESC-Qualified Matrix should be aliquoted and frozen. Consult the Matrigel® Certificate of Analysis for the recommended aliquot size ("Dilution Factor") to prepare 25 mL of diluted matrix. Always keep Matrigel® on ice when thawing and handling to prevent it from gelling.

Note: Use tissue culture-treated cultureware (e.g. Falcon® 6-Well Flat-Bottom Plate, Tissue Culture-Treated, Catalog #38016) with Corning® Matrigel®.

1. Thaw one aliquot of Matrigel® on ice.
2. Dispense 25 mL of cold DMEM/F-12 with 15 mM HEPES into a 50 mL conical tube and keep on ice.
3. Add thawed Matrigel® to the cold DMEM/F-12 (in the 50 mL tube) and mix well. The vial may be washed with cold medium if desired.
4. Immediately use the diluted Matrigel® solution to coat tissue culture-treated cultureware. See Table 1 for recommended coating volumes.
5. Swirl the cultureware to spread the Matrigel® solution evenly across the surface.

Note: If the cultureware surface is not fully coated by the Matrigel® solution, it should not be used for human ES or iPS cell culture.

6. Incubate at room temperature (15 - 25°C) for at least 1 hour before use. Do not let the Matrigel® solution evaporate.

Note: If not used immediately, the cultureware must be sealed to prevent evaporation of the Matrigel® solution (e.g. with Parafilm®) and can be stored at 2 - 8°C for up to 1 week after coating. Allow stored coated cultureware to come to room temperature (15 - 25°C) for 30 minutes before proceeding to step 7.

7. Gently tilt the cultureware onto one side and allow the excess Matrigel® solution to collect at the edge. Remove the excess solution using a serological pipette or by aspiration. Ensure that the coated surface is not scratched.
8. Immediately add TeSR™-E8™ (e.g. 2 mL/well if using a 6-well plate).

4.2.2 Vitronectin XF™

Note: Use non-tissue culture-treated cultureware (e.g. Non Tissue Culture-Treated 6-Well Plates; Catalog #27147) with Vitronectin XF™.

1. Thaw Vitronectin XF™ at room temperature (15 - 25°C).
2. Dilute Vitronectin XF™ in CellAdhere™ Dilution Buffer to reach a final concentration of 10 µg/mL (i.e. use 40 µL of Vitronectin XF™ per mL of CellAdhere™ Dilution Buffer). Use a 50 mL polypropylene conical tube (e.g. Catalog #38010) to dilute Vitronectin XF™.
3. Gently mix the diluted Vitronectin XF™. Do not vortex.
4. Immediately use the diluted Vitronectin XF™ solution to coat non-tissue culture-treated cultureware. See Table 1 for recommended coating volumes.
5. Gently rock the cultureware back and forth to spread the solution evenly across the surface.

Note: If the cultureware surface is not fully coated by the Vitronectin XF™ solution, it should not be used for human ES or iPS cell culture.

6. Incubate at room temperature (15 - 25°C) for at least 1 hour before use. Do not let the solution evaporate.

Note: If not used immediately, the cultureware must be sealed to prevent evaporation of the Vitronectin XF™ solution (e.g. with Parafilm®) and can be stored at 2 - 8°C for up to 1 week after coating. Allow stored coated cultureware to come to room temperature (15 - 25°C) for 30 minutes before proceeding to step 7.

7. Gently tilt the cultureware onto one side and allow the excess Vitronectin XF™ solution to collect at the edge. Remove the excess solution using a serological pipette or by aspiration. Ensure that the coated surface is not scratched.
8. Wash the cultureware once using CellAdhere™ Dilution Buffer (e.g. use 2 mL/well if using a 6-well plate).
9. Aspirate wash solution and add TeSR™-E8™ (e.g. 2 mL/well if using a 6-well plate).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

5.0 Enzyme-Free Passaging of Human ES and iPS Cells Cultured in TeSR™-E8™

Human ES and iPS cells maintained in TeSR™-E8™ can be passaged using non-enzymatic methods that are described in this section. Enzymatic passaging reagents such as Dispase are not recommended for use with TeSR™-E8™.

The passaging protocols described in this section use enzyme-free dissociation methods to remove colonies from the cultureware. The cell aggregates generated using these protocols may be fragile, and they should be replated as quickly as possible.

5.1 ReLeSR™

ReLeSR™ is an enzyme-free reagent for dissociation and passaging of human ES and iPS cells as aggregates without manual selection of differentiated areas or scraping to remove cell aggregates. The following protocol is recommended when first culturing cells in TeSR™-E8™.

The following instructions are for passaging cells from one well of a 6-well plate. If using other cultureware, adjust volumes accordingly.

1. At least 1 hour before passaging, coat new plates with either Corning® Matrigel® (section 4.2.1) or Vitronectin XF™ (section 4.2.1).
2. Aliquot sufficient TeSR™-E8™ and warm to room temperature (15 - 25°C).
Note: Do not warm TeSR™-E8™ in a 37°C water bath.
3. Wash cells with 1 mL of D-PBS (Without Ca++ and Mg++) and aspirate.
Note: There is no need to remove regions of differentiated cells.
4. Add 1 mL of ReLeSR™ and aspirate ReLeSR™ within 1 minute, so that colonies are exposed to a thin film of liquid.
5. Incubate at room temperature (15 - 25°C) for 7 - 9 minutes.
Note: Optimal dissociation time may vary depending on the cell line used; when passaging a cell line with ReLeSR™ for the first time, the optimal dissociation time should be determined (see Figure 9 and section 8.0).
6. Add 1 mL of TeSR™-E8™.
7. Detach the colonies by placing the plate on a plate vortexer (e.g. Multi-MicroPlate Genie, 120 V, Scientific Industries Model SI-4000, at 1200 rpm) for 2 - 3 minutes at room temperature (15 - 25°C). Alternatively, hold the plate with one hand and use the other hand to firmly tap the side of the plate for approximately 30 - 60 seconds.
8. Transfer the detached cell aggregates to a 15 mL conical tube using a 5 mL serological pipette (e.g. Catalog #38003). Cell aggregates should be appropriately sized for plating (mean aggregate size of approximately 50 - 200 µm; see Figure 9).
Note: If you wish to plate cell aggregates directly from your passaged well (i.e. without transferring into a tube), pipette the aggregate mixture up and down once using a 5 mL pipette. This will ensure breakup of any large aggregates that may still be present.
9. Plate the cell aggregate mixture at the desired density onto coated wells containing TeSR™-E8™. If the colonies are at an optimal density, the cultures can be split every 4 - 7 days using 1 in 10 to 1 in 50 splits (i.e. cell aggregates from 1 well can be plated in 10 to 50 wells). If the colonies are too dense or too sparse, at the next time of passaging adjust the split ratio accordingly (see section 6.2).
10. Place the plate in a 37°C incubator. Move the plate in several quick, short, back-and-forth and side-to-side motions to evenly distribute the cell aggregates. Do not disturb the plate for 24 hours.

Note: Uneven distribution of aggregates may result in increased differentiation of human ES and iPS cells.

11. Perform daily medium changes using TeSR™-E8™ and visually assess cultures to monitor growth until the next passaging time.




Figure 9. Effect of ReLeSR™ on Human Pluripotent Cells Cultured in TeSR™-E8™

Examples of ideal cell aggregates (mean size of approximately 50 - 200 µm) obtained after step 8 of the ReLeSR™ passaging protocol. Magnifications: (A) 20X and (B) 100X. If cell aggregates do not resemble these examples, the passaging protocol may require further optimization (for more information, refer to “Cell aggregate size obtained with ReLeSR™ is not ideal” in section 8.0).

5.2 Gentle Cell Dissociation Reagent (GCDR)

Gentle Cell Dissociation Reagent (GCDR) is an enzyme-free reagent for passaging of human ES and iPS cells as aggregates with manual scraping to generate cell aggregates. Once familiar with the following protocol, it is possible to adjust the time at which cells are ready to be passaged by altering the cell aggregate size (section 6.1) or plating density (section 6.2).

The following instructions are for passaging cells from one well of a 6-well plate. If using other cultureware, adjust volumes accordingly.

1. At least 1 hour before passaging, coat new plates with either Corning® Matrigel® (section 4.2.1) or Vitronectin XF™ (section 4.2.1).
2. Aliquot sufficient complete TeSR™-E8™ and warm to room temperature (15 - 25°C).
Note: Do not warm complete TeSR™-E8™ in a 37°C water bath.
3. Use a microscope to visually identify regions of differentiation. Mark these using a felt tip or lens marker on the bottom of the plate.
4. Remove regions of differentiation by scraping with a pipette tip or by aspiration. Avoid having the culture plate out of the incubator for more than 15 minutes at a time.

Note: Selection may not be required if differentiation is < 5%. Selection should not exceed 20% of the well if the culture is of high quality. For representative pictures of regions of differentiation see Figure 1B, Figure 2B, Figure 3B, and Figure 4B.

5. Aspirate medium from the well and add 1 mL of GCDR.
6. Incubate at room temperature (15 - 25°C). Refer to Table 2 for recommended incubation times.

Table 2. GCDR Incubation Times for Cultures Plated on Different Matrices

MATRIX	INCUBATION TIME WITH GCDR*	REPRESENTATIVE EXAMPLE
Vitronectin XF™	6 - 12 minutes	Figure 10
Corning® Matrigel®	6 - 8 minutes	Figure 11

*Incubation times may vary when using different cell lines or other non-enzymatic cell passaging reagents; dissociation should be monitored under the microscope until the optimal time is determined.

- Aspirate the GCDR and add 1 mL of TeSR™-E8™. Gently detach the colonies by scraping with a serological glass pipette or a cell scraper.
Note: Take care to minimize the breakup of colonies.
- Transfer the detached cell aggregates to a 15 mL conical tube.
Optional: Rinse the well with an additional 1 mL of TeSR™-E8™ to collect remaining cell aggregates.
Note: Centrifugation of cell aggregates is not required.
- Carefully pipette the cell aggregate mixture up and down to break up the aggregates as needed. Refer to Table 3 for suggestions on how to break up cell aggregates grown on different types of matrices. A uniform suspension of aggregates approximately 50 - 200 µm in size is optimal; do not create a single-cell suspension (for more information, see section 8.0).

Table 3. Suggested Methods for Breaking Up Cell Aggregates

MATRIX	PIPETTE TYPE	# OF TIMES TO PIPETTE UP AND DOWN*
Vitronectin XF™	1 mL pipettor	1 - 2
Corning® Matrigel®	2 mL serological pipette	2 - 5

*Number can be adjusted to obtain desired cell aggregate size (section 6.1). Refer to Figure 12 for examples of appropriate cell aggregate sizes, and adjust procedure as necessary to achieve desired results.

- Plate cell aggregate mixture at the desired density onto coated wells containing TeSR™-E8™. If the colonies are at an optimal density, the cultures can be split every 4 - 7 days using 1 in 10 to 1 in 50 splits (i.e. cell aggregates from 1 well can be plated in 10 - 50 wells). If the colonies are too dense or too sparse, at the next time of passaging adjust the split ratio accordingly (see section 6.2).
Note: Work quickly to transfer cell aggregates into new cultureware to maximize viability and attachment.
- Place the plate in a 37°C incubator. Move the 6-well plate in several quick, short, back-and-forth and side-to-side motions to distribute the cell aggregates. Do not disturb the plate for 24 hours.
Note: Uneven distribution of aggregates may result in increased differentiation of human ES and iPS cells.
- Perform daily medium changes using TeSR™-E8™ and visually assess cultures to monitor growth until the next passaging time.




Figure 10. Effect of Gentle Cell Dissociation Reagent on Human ES Cells Cultured on Vitronectin XF™ in TeSR™-E8™

Human ES cells (H9) at different timepoints during incubation with Gentle Cell Dissociation Reagent.

Magnifications: 20X, 40X, and 100X. Recommended incubation time (6 - 12 minutes) occurs when gaps appear between cells located on the edges of the colonies. At earlier timepoints the colonies are not sufficiently dissociated, whereas at later timepoints the colonies are excessively dissociated and may break up into unwanted single cells upon scraping.

Note: The incubation time may vary when using different cell lines or other non-enzymatic cell passaging reagents; dissociation should be monitored under the microscope until the optimal time is determined based on appearance.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.




Figure 11. Effect of Gentle Cell Dissociation Reagent on Human iPS Cells Cultured on Corning® Matrigel® in TeSR™-E8™

Human iPS cells (A13700) at different timepoints during incubation with Gentle Cell Dissociation Reagent. Magnifications: 20X, 40X, and 100X. Recommended incubation time (6 - 8 minutes) occurs when gaps are beginning to appear between cells located on the edges of the colonies. At earlier timepoints the colonies are not sufficiently dissociated, whereas at later timepoints the colonies are excessively dissociated and may break up into unwanted single cells upon scraping.

Note: The incubation time may vary when using different cell lines or other non-enzymatic cell passaging reagents; dissociation should be monitored under the microscope until the optimal time is determined based on appearance.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

6.0 Customizing the Passaging Protocol

Culturing human ES and iPS cells in TeSR™-E8™ allows some flexibility in the passaging schedule, as cultures can be passaged between 4 and 7 days after plating in TeSR™-E8™. The next time the cells are ready for passaging depends on the size and density of the plated cell aggregates. For example, if large cell aggregates are plated at a high density, the next passaging time will most likely occur on day 4 or 5, whereas if small cell aggregates are plated at a low density, the next passaging will most likely occur on day 6 or 7 (Table 4). For representative images of large and small cell aggregates, see Figure 12. Regardless of the plating density and cell aggregate size used, the majority of colonies should be densely packed and multi-layered in the center when ready for passage.

Table 4. Parameters Affecting Next Passaging Time

AT TIME OF PLATING		AT TIME OF PASSAGING	
CELL AGGREGATE SIZE*	PLATING DENSITY	COLONY DENSITY**	DAYS IN CULTURE
Large	High	High	4 - 5
Large	Low	Low	5 - 6
Medium	Medium	Medium	
Small	High	High	
Small	Low	Low	6 - 7

*For representative images see Figure 12.

**For representative images see Figure 13.

6.1 Cell Aggregate Size

At the time of plating, the desired cell aggregate size can be obtained by adjusting the number of times the cell aggregate suspension is pipetted up and down (Table 3). Refer to Figure 12 for a recommended range of cell aggregate sizes. Do not generate single cells.




Figure 12. Acceptable Size Range for Cell Aggregates at the Time of Plating

Cell aggregate size can be adjusted by altering the number of times the cell aggregate mixture is pipetted up and down (see Table 3). Avoid generating single cells. Magnifications: 40X and 100X.

6.2 Colony Density at Time of Passaging

The number of cell aggregates plated at the time of passaging is correlated to the colony density observed at the next time of passaging. By altering the split ratios at the time of plating you can increase or decrease the colony density as desired. For example, a lower split ratio at the time of plating (i.e. plating more cell aggregates) will result in a higher colony density at the next passaging time. Typical split ratios are 1 in 10 to 1 in 50; however, this can vary depending on the cell line used and the individual operator. Refer to Figure 13 for a recommended range of colony densities that should be observed at the time of passage. Some cell lines may show increased spontaneous differentiation when cultured at higher densities; if increased differentiation is observed, the colony density may be decreased in the next passage by plating fewer cell aggregates. Counting cell aggregates is an alternate way to determine and adjust plating densities (see Appendix 1).




Figure 13. Example Colony Densities for Cultures Grown on Either Vitronectin XF™ or Corning® Matrigel® in TeSR™-E8™

Human ES cells (H1) were cultured in TeSR™-E8™ and stained with Giemsa at the optimal time of passaging (the optimal time of passaging may be different for each colony density; see Table 4). Each image represents a single well of a 6-well plate.

7.0 Additional Protocols

7.1 Transitioning Cells

7.1.1 From Feeder-Free Media to TeSR™-E8™

No adaptation step is required when plating human ES and iPS cells from mTeSR™1, mTeSR™ Plus, TeSR™2, or other feeder-free maintenance medium to TeSR™-E8™.

Follow an enzyme-free passaging protocol from section 5.0 and plate cell aggregates onto coated cultureware containing TeSR™-E8™. It is recommended that a culture using the previous feeder-free medium and culture system is initially maintained in parallel to ensure that the chosen plating density in TeSR™-E8™ is appropriate.

Cells may experience an increase in spontaneous differentiation in the first 1 - 2 passages after transfer. Removal of differentiated regions either manually or using a specialized dissociation reagent such as ReLeSR™ (section 5.1) will help ensure that the culture quickly adapts to the new environment without affecting the long-term health of the culture.

Note: Use of enzymatic (e.g. Dispase) passaging protocols is not recommended when transitioning cells from feeder-free media to TeSR™-E8™.

7.1.2 From TeSR™-E8™ to mTeSR™1, mTeSR™ Plus, or TeSR™2

No adaptation step is required when plating human ES and iPS cells from TeSR™-E8™ to mTeSR™1, mTeSR™ Plus, or TeSR™2. Follow an enzyme-free passaging protocol (section 5.0) and replate cell aggregates onto coated cultureware containing mTeSR™1, mTeSR™ Plus, or TeSR™2. Do not use enzymatic passaging protocols.

Cells may experience an increase in spontaneous differentiation in the first 1 - 2 passages after transfer. Removal of differentiated regions either manually, or using a specialized dissociation reagent such as ReLeSR™ (section 5.1) will help to ensure that the culture quickly adapts to the new environment without affecting the long-term health of the culture.

7.1.3 Cultured on Corning® Matrigel® to Vitronectin XF™

Human ES and iPS cells cultured on Corning® Matrigel® in TeSR™-E8™ may be conveniently transitioned to Vitronectin XF™ without an adaptation step. When cells are ready for passaging, follow the protocol in section 5.0 as though you were to plate cells back onto Corning® Matrigel® (i.e. use incubation times recommended for Corning® Matrigel® in Table 2; however, ensure that the cell aggregates are plated on Vitronectin XF™-coated cultureware (section 4.2.2). For subsequent passages, an enzyme-free passaging protocol (section 5.0) for cells cultured on Vitronectin XF™ may then be used. Do not use an enzymatic passaging protocol when transitioning cells to Vitronectin XF™.

Note: Both the medium and the matrix can be changed at the same time (e.g. cells cultured on Corning® Matrigel® using mTeSR™1 may be transitioned onto Vitronectin XF™ with TeSR™-E8™ in one step; see section 7.1.1).

7.1.4 Cultured on a Feeder Layer to TeSR™-E8™

Human ES and iPS cells cultured on a layer of feeder cells may be conveniently transferred to feeder-free conditions with TeSR™-E8™. Cell aggregates can be harvested using protocols established in your institute for feeder-dependent cells and plated on the desired matrix in TeSR™-E8™. Alternatively, use the protocol below. Plating efficiency can be affected during the transition, therefore initial plating of cell aggregates at 2 - 3 times higher density than routinely used for passaging may improve adaptation of cells to feeder-free conditions.

The following instructions are for passaging cells from one well of a 6-well plate. If using other cultureware, adjust volumes accordingly.

1. At least 1 hour before passaging, coat new plates with either Corning® Matrigel® (section 4.2.1) or Vitronectin XF™ (section 4.2.1).
2. Aliquot sufficient complete TeSR™-E8™, DMEM/F-12 with 15 mM HEPES, and Collagenase Type IV (Catalog #07909). Warm to room temperature (15 - 25°C).

Note: Do not warm complete TeSR™-E8™ medium in a 37°C water bath.

3. Use a microscope to visually identify regions of differentiation. Mark these using a felt tip or lens marker on the bottom of the plate. Remove regions of differentiation by scraping with a pipette tip or by aspiration.

Note: This selection should not exceed 20% of the well if the culture is of high quality.

4. Aspirate medium from the well and add 1 mL of Collagenase Type IV.
5. Incubate at 37°C for 20 minutes.

Note: The incubation time may vary when using different cell lines or other enzymatic cell passaging reagents, therefore dissociation should be monitored under the microscope until the optimal time is determined.

6. Aspirate the collagenase, and wash the well twice with 1 mL of DMEM/F-12 with 15 mM HEPES.
7. Add 1 mL of TeSR™-E8™. Gently detach the colonies by scraping with a serological glass pipette or a cell scraper.
8. Transfer the detached cell aggregates to a 15 mL conical tube.
Optional: Rinse the well with an additional 1 - 2 mL of TeSR™-E8™ to collect remaining cell aggregates. Add the rinse to the 15 mL tube.
9. Carefully pipette the cell aggregate mixture up and down 2 - 3 times with a 2 mL serological pipette (e.g. Catalog #38002) to break up the cell aggregates. A uniform suspension of aggregates approximately 50 - 200 µm in size is optimal; do not create a single-cell suspension (see section 8.0).
10. Plate cell aggregate mixture at the desired density onto coated wells containing TeSR™-E8™.

Note: Feeder cells will continue to be present in the first 1 - 2 passages after transition, but should not persist beyond passage 2 following transfer. It is recommended that a culture grown on a layer of feeder cells is initially maintained in parallel to ensure that the chosen plating density in TeSR™-E8™ is appropriate.

11. Place the plate in a 37°C incubator. Move the plate in several quick, short, back-and-forth and side-to-side motions to evenly distribute the cell aggregates. Do not disturb the plate for 24 hours.

Note: Uneven distribution of aggregates may result in increased differentiation of human ES and iPS cells.

12. Perform daily medium changes using TeSR™-E8™ and visually assess cultures to monitor growth until the next passaging time.

7.2 Preparing a Single-Cell Suspension for Downstream Applications

The following are instructions for preparing a single-cell suspension from cultures grown in TeSR™-E8™ in 6-well plates. If using other cultureware, adjust volumes accordingly. Cultures should be harvested and frozen at the time they would normally be ready for passaging.

1. Warm medium (DMEM/F-12 with 15 mM HEPES or TeSR™-E8™), Gentle Cell Dissociation Reagent, and D-PBS (Without Ca++ and Mg++) to room temperature (15 - 25°C) before use.

Note: Do not warm TeSR™-E8™ in a 37°C water bath.

2. Wash the well to be passaged with 1 mL of D-PBS (Without Ca++ and Mg++).
3. Aspirate the wash medium and add 1 mL of Gentle Cell Dissociation Reagent. Incubate at 37°C for 8 - 10 minutes.

Note: The incubation time may vary when using different cell lines or other cell passaging reagents.

4. Harvest cells by pipetting up and down with either a serological pipette or a 1 mL pipettor to ensure a single-cell suspension and transfer cells to a 15 mL conical tube. Rinse wells with an additional 2 - 4 mL of medium (DMEM/F-12 with 15 mM HEPES or TeSR™-E8™) and add the rinse to the tube containing the cells.

5. Centrifuge cells at 300 x g for 5 minutes.

6. Resuspend cells in appropriate medium for desired downstream applications.

Note: Addition of 10 µM Y-27632 (ROCK inhibitor) is recommended when plating single-cell suspensions of human ES or iPS cells, as it has been reported to increase cell survival. Alternatively, addition of CloneR™ is recommended when plating single cells at low or clonal densities to improve survival and cloning efficiency.

7.3 Cryopreserving and Thawing Cells

Human pluripotent stem cells maintained in TeSR™-E8™ can be cryopreserved as aggregates using CryoStor® CS10 or as single cells using FreSR™-S. Either cryopreservation method is appropriate for use with cultures routinely passaged as aggregates using the methods described in this manual.

The thawing protocols are for human ES and iPS cells that were maintained in TeSR™-E8™ prior to cryopreservation. Cells cultured using other maintenance protocols (e.g. on a layer of feeders or their conditioned medium, or feeder-free media such as mTeSR™ 1, mTeSR™ Plus, or TeSR™ 2) should be thawed into the same medium and conditions used prior to cryopreservation. Once they have recovered from the thaw, cells can be transitioned into TeSR™-E8™ (sections 7.1.1 and 7.1.4).

7.3.1 CryoStor® CS10 (Cell Aggregates)

CryoStor® CS10 is an animal component-free cryopreservation medium. It is ready to use and contains cryoprotectant agents.

Cryopreserving Cells

Note: Wipe down the outside of the bottle with 70% ethanol or isopropanol before opening.

The following are instructions for cryopreserving cultures grown in TeSR™-E8™ in 6-well plates. Cultures should be harvested and cryopreserved at the time they would normally be ready for passaging. Each vial should contain the cell aggregates from one well of a 6-well plate. If using other cultureware, adjust volumes accordingly.

1. Passage cells using enzyme-free passaging protocols (section 5.1 or 5.2) until step 8.
2. Centrifuge at 300 x *g* for 5 minutes at room temperature (15 - 25°C).
3. Gently aspirate the supernatant, taking care not to disrupt the cell pellet.
4. Gently resuspend the pellet with 1 mL per well harvested of cold (2 - 8°C) CryoStor® CS10 using a serological pipette. Minimize the breakup of cell aggregates when dislodging the pellet.
5. Transfer 1 mL of cell aggregates in CryoStor® CS10 into each labeled cryovial using a 2 mL serological pipette.
6. Cryopreserve cell aggregates using either:
 - A standard slow rate-controlled cooling protocol that reduces temperatures at approximately -1°C/min, followed by long-term storage at -135°C (liquid nitrogen) or colder. Long-term storage at -80°C is not recommended.
 - A multi-step protocol where cells are kept at -20°C for 2 hours, followed by -80°C for 2 hours, followed by long-term storage at -135°C (liquid nitrogen) or colder.

Thawing Cells

Human ES and iPS cells should be thawed into coated cultureware (section 4.2). In general, one vial of cells cryopreserved as described above can be successfully thawed into 1 - 2 wells of a 6-well plate.

1. Have all tubes, warmed TeSR™-E8™ (15 - 25°C), and coated cultureware ready before starting the protocol to ensure that the thawing procedure is done as quickly as possible.

Note: Do not warm TeSR™-E8™ in a 37°C water bath.

2. Wipe the outside of the vial of cells with 70% ethanol or isopropanol.
3. In a biosafety cabinet, twist the cap a quarter-turn to relieve internal pressure, then retighten.
4. Quickly thaw the cells in a 37°C water bath by gently shaking the vial. Remove the vial when a small frozen cell pellet remains. Do not vortex cells.

5. Wipe the outside of the vial with 70% ethanol or isopropanol.
6. Use a 2 mL serological pipette (e.g. Catalog #38002) to transfer the contents of the cryovial to a 15 mL conical tube.
Note: Using a 2 mL serological pipette instead of a 1 mL pipettor will minimize breakage of cell aggregates.
7. Add 5 - 7 mL of warm TeSR™-E8™ dropwise to the 15 mL tube, gently mixing as the medium is added.
8. Centrifuge cells at 300 x g for 5 minutes at room temperature (15 - 25°C).
9. Aspirate the medium, leaving the cell pellet intact. Gently resuspend the cell pellet in 1 mL of TeSR™-E8™ using a 2 mL serological pipette. Take care to maintain the cells as aggregates.
10. Transfer 0.5 mL of the cell mixture into one well of a coated 6-well plate containing TeSR™-E8™ (i.e. two wells can be plated from each cryovial).

Note: Number of wells plated may need to be adjusted depending on how many cell aggregates were cryopreserved. Typically many more aggregates will need to be plated after thawing than during routine passaging.

11. Place the plate in a 37°C incubator. Move the 6-well plate in several quick, short, back-and-forth and side-to-side motions to distribute the cell aggregates. Do not disturb the plate for 24 hours.

Note: Uneven distribution of aggregates may result in increased differentiation of human ES and iPS cells.

12. Perform daily medium changes using TeSR™-E8™ and visually assess cultures to monitor growth until the next passaging time. Check for undifferentiated colonies that are ready to be passaged (dense-centered) approximately 6 - 7 days after thawing.

Note: If only a few undifferentiated colonies are observed after thawing, it may be necessary to select only these colonies for passaging and replat them in the same size well (i.e. without splitting) on a newly coated culture plate.

7.3.2 FreSR™-S (Single Cells)

FreSR™-S is a defined, serum-free, and animal component-free medium for cryopreserving human ES/iPS cells as single cells. It is ready to use and contains cryoprotectant agents.

Cryopreserving Cells

Note: Wipe down the outside of the bottle with 70% ethanol or isopropanol before opening.

The following are instructions for cryopreserving cultures grown in TeSR™-E8™ in 6-well plates. If using other cultureware, adjust volumes accordingly. Cultures should be harvested and cryopreserved at the time they would normally be ready for passaging.

1. Warm medium (DMEM/F-12 with 15 mM HEPES or TeSR™-E8™), Gentle Cell Dissociation Reagent, and D-PBS (Without Ca++ and Mg++) to room temperature (15 - 25°C) before use.

Note: Do not warm TeSR™-E8™ in a 37°C water bath.

2. Wash the well to be passaged with 1 mL of D-PBS (Without Ca++ and Mg++).
3. Aspirate the wash medium and add 1 mL of Gentle Cell Dissociation Reagent. Incubate at 37°C for 8 - 10 minutes.

Note: The incubation time may vary when using different cell lines or other cell passaging reagents.

4. Harvest cells by pipetting up and down with either a serological pipette or a 1 mL pipettor to ensure a single-cell suspension and transfer cells to a 15 mL conical tube. Rinse wells with an additional 2 - 4 mL of medium (DMEM/F-12 with 15 mM HEPES or TeSR™-E8™) and add the rinse to the tube containing the cells.
5. Perform a viable cell count using Trypan Blue and a hemocytometer.
6. Centrifuge cells at 300 x g for 5 minutes at room temperature (15 - 25°C).
7. Carefully remove the supernatant with a pipette, leaving a small amount of medium to ensure the cell pellet is not disturbed. Resuspend the cell pellet by gently flicking the tube.
8. Add cold (2 - 8°C) FreSR™-S to obtain a cell suspension of 1 x 10⁶ cells/mL and mix thoroughly.
9. Transfer 1 mL of the single-cell suspension into each cryovial.
10. Cryopreserve cells using either:
 - A standard slow rate-controlled cooling protocol that reduces temperatures at approximately -1°C/min, followed by long-term storage at -135°C (liquid nitrogen) or colder. Long-term storage at -80°C is not recommended.
 - A multi-step protocol where cells are kept at -20°C for 2 hours, followed by -80°C for 2 hours, followed by long-term storage at -135°C (liquid nitrogen) or colder.

Thawing Cells

Human ES and iPS cells should be thawed into coated cultureware (section 4.2). In general, one vial of 1×10^6 cells cryopreserved as described above can be successfully thawed into 1 - 2 wells of a 6-well plate.

1. Have all tubes, warmed TeSR™-E8™ (15 - 25°C) and DMEM/F-12 with 15 mM HEPES, and coated cultureware ready before starting the protocol to ensure that the thawing procedure is done as quickly as possible.

Note: Do not warm TeSR™-E8™ in a 37°C water bath.

2. Add Y-27632 to TeSR™-E8™ to reach a final concentration of 10 µM.
3. Wipe the outside of the vial with 70% ethanol or isopropanol.
4. In a biosafety cabinet, twist the cap a quarter-turn to relieve internal pressure, then retighten.
5. Quickly thaw cells in a 37°C water bath by gently shaking the vial. Remove the vial when a small frozen cell pellet remains. Do not vortex cells.
6. Wipe the outside of the vial with 70% ethanol or isopropanol.
7. Use a 1 mL pipettor to slowly transfer the contents of the cryovial to a 15 mL conical tube containing 5 - 7 mL of DMEM/F-12 with 15 mM HEPES.
8. Centrifuge cells at 300 x g for 5 minutes at room temperature (15 - 25°C).
9. Carefully remove the supernatant with a pipette, leaving a small amount of medium to ensure the cell pellet is not disturbed.
10. Add 1 mL of TeSR™-E8™ containing 10 µM Y-27632 to the tube. Mix gently.
11. Plate cells onto coated cultureware.

Note: In general, one frozen cryovial containing 1×10^6 cells can be thawed and plated into 1 - 2 wells of a 6-well plate.

12. Place the cultureware in a 37°C incubator. Move the cultureware in several quick, short, back-and-forth and side-to-side motions to evenly distribute the cells across the surface.
13. Perform daily medium changes using TeSR™-E8™ (without Y-27632) and visually assess cultures to monitor growth until the next passaging time (i.e. 80 - 90% confluent). This takes approximately 2 - 5 days after thawing.

Note: The time to reach 80 - 90% confluency may vary when using different cell lines; cultures should be monitored under the microscope until the optimal passaging time is determined.

14. Passage cultures using standard techniques to generate cell aggregates (e.g. ReLeSR™ [section 5.1]).

Note: It is not recommended to perform serial single-cell passaging due to the increased risk of karyotype abnormalities.^{1,2}

8.0 Troubleshooting

PROBLEM	SOLUTION
Excessive differentiation (> 20%) in cultures	<ul style="list-style-type: none"> • Ensure the freshly prepared complete TeSR™-E8™ medium kept at 2 - 8°C is less than 2 weeks old and is stored in either the TeSR™-E8™ Basal Medium bottle or 50 mL polypropylene tubes (e.g. Catalog #38010). If frozen complete medium is thawed, use within 2 weeks. • Ensure areas of differentiation are removed prior to passaging. • Avoid having the culture plate out of the incubator for more than 15 minutes at a time. • Ensure that the cell aggregates generated after passaging are evenly sized. • Decrease the colony density by plating fewer cell aggregates during passaging. • Reduce incubation time with the ReLeSR™ during passaging, as your cell line/culture may be more sensitive.
Cell aggregate size obtained with ReLeSR™ (section 5.1) is not ideal (i.e. aggregates do not look like the example in Figure 9)	<ul style="list-style-type: none"> • Larger aggregates are obtained (i.e. mean aggregate size is > 200 µm) <ul style="list-style-type: none"> ◦ Pipette the cell aggregate mixture up and down. Avoid generating a single-cell suspension. ◦ Increase the incubation time by 1 - 2 minutes. ◦ Increase the incubation temperature to 37°C. • Smaller aggregates are obtained (i.e. mean aggregate size is < 50 µm) <ul style="list-style-type: none"> ◦ Minimize the manipulation of cell aggregates after dissociation. ◦ Decrease the incubation time by 1 - 2 minutes.
Cell aggregates obtained during the passaging protocol are too large	<ul style="list-style-type: none"> • Increase the incubation temperature to 37°C or the incubation time with ReLeSR™. • Increase the incubation time with Gentle Cell Dissociation Reagent. • Increase pipetting up and down of the cell aggregates. • Add a wash step using D-PBS (Without Ca++ and Mg++) before adding the non-enzymatic passaging reagents.
Differentiated cells are also detaching with the colonies when using ReLeSR™	<ul style="list-style-type: none"> • Decrease the incubation time with ReLeSR™ by 1 - 2 minutes.
Colonies remain attached and/or significant scraping is required to dislodge cells	<ul style="list-style-type: none"> • Ensure that the passaging reagents are used as described in section 5.0. • Increase the incubation time by 1 - 2 minutes. • Increase the incubation temperature to 37°C when using ReLeSR™.
Low attachment observed after plating	<ul style="list-style-type: none"> • Plate a higher number of cell aggregates initially (e.g. 2 - 3 times higher) and maintain a more densely confluent culture. • Work quickly after cells are treated with the passaging reagents (ReLeSR™ or Gentle Cell Dissociation Reagent) to minimize the duration that cell aggregates are in suspension. • Reduce incubation time with the passaging reagent during passaging, as your cell line/culture may be more sensitive. This is particularly important if cells are passaged prior to cell multi-layering within the colony. • Do not excessively pipette up and down to break up cell aggregates to reach the desired size. Instead, increase the incubation time with the passaging reagent by 1 - 2 minutes. This is particularly important if colonies are very dense and cell aggregates are difficult to break up. • Ensure that non-tissue culture-treated plates are used when coating with Vitronectin XF™; ensure that tissue culture-treated plates are used when coating with Corning® Matrigel®.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

PROBLEM	SOLUTION
Single cells are generated during colony dissociation	<ul style="list-style-type: none"> • Work quickly after cells are treated with passaging reagents to minimize the time that cell aggregates are in suspension. • Reduce incubation time with the passaging reagents during passaging, as your cell line/culture may be more sensitive. This is particularly important if cells are passaged prior to cell multi-layering within the colony. • Minimize the manipulation of cell aggregates after dissociation.
Cells do not adhere to the coated cultureware	<ul style="list-style-type: none"> • Avoid using enzymatic passaging reagents (e.g. Dispase). • Ensure that non-tissue culture-treated plates are used when coating with Vitronectin XF™.
Cells detach during Day 1 medium change	<ul style="list-style-type: none"> • Gently change medium during cell feeding. • Start changing medium on Day 2 after initial plating of cells to allow cell aggregates to fully attach.
Low cell expansion	<ul style="list-style-type: none"> • Allow cells to culture longer prior to passaging. The majority of cell expansion occurs just prior to optimal passage points.
Non-uniform cell aggregate attachment	<ul style="list-style-type: none"> • Ensure that the well is completely covered with the culture matrix during the coating step and has not evaporated prior to use. • Ensure that cell aggregates are evenly distributed throughout the well when placing in the incubator and that the plate is not disturbed for 24 hours after plating.

9.0 References

1. Draper JS et al. (2004) Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. *Nat Biotechnol* 22(1): 53–4.
2. Buzzard JJ et al. (2004) Karyotype of human ES cells during extended culture. *Nat Biotechnol* 22(4): 381–2.
3. Mitalipova MM et al. (2005) Preserving the genetic integrity of human embryonic stem cells. *Nat Biotechnol* 23(1): 19–20.
4. Chen G et al. (2011) Chemically defined conditions for human iPSC derivation and culture. *Nat Methods* 8(5): 424–9.
5. Beers J et al. (2012) Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. *Nat Protoc* 7(11): 2029–40.
6. Ludwig TE et al. (2006) Derivation of human embryonic stem cells in defined conditions. *Nat Biotechnol* 24(2): 185–7.
7. Ludwig TE et al. (2006) Feeder-independent culture of human embryonic stem cells. *Nat Methods* 3(8): 637–46.

Appendix 1: Plating Human ES and iPS Cells Using the Cell Aggregate Count Method

Counting cell aggregates is an alternate way to determine and adjust plating densities; it allows a more controlled way to plate an appropriate number of cell aggregates at the time of passaging. This can be a valuable learning tool for those new to human ES and iPS cell culture.

In the protocol below, count cell aggregates $\geq 50 \mu\text{m}$ in diameter, as these are the most likely to attach and grow into healthy colonies. An eyepiece micrometer can help to identify cell aggregates of this size. The following protocol should be carried out during passaging at the time of plating cell aggregates. Refer to section 5.0 for detailed passaging protocols.

1. Draw a "+" centered on the bottom of 2 wells of a 96-well flat-bottom plate (e.g. Catalog #38044) to serve as a counting grid.
2. Aliquot 40 μL of DMEM/F-12 with 15 mM HEPES into each well.
3. Add 5 μL of a freshly resuspended cell aggregate mixture to each well.
4. Count the cell aggregates in each well that are approximately $\geq 50 \mu\text{m}$ in diameter. Average the results from the two wells to obtain the average number of cell aggregates (N_A) in the 5 μL sample.
5. Calculate the concentration of cell aggregates (C) and the total number of cell aggregates in the mixture (N_T) using the total volume of the mixture (V_T):

$$C = \frac{N_A}{5 \mu\text{L}}$$

$$N_T = C \times V_T$$

6. Determine the target number of cell aggregates to plate (N_P , refer to Table 5). Ensure that the total target number of cell aggregates to plate for all conditions in your experiment (i.e. $N_P \times$ number of conditions) does not exceed N_T .

Table 5. Recommended Number of Cell Aggregates to Plate

CULTUREWARE	TARGET # OF CELL AGGREGATES TO PLATE (N_P , PLATING DENSITY)		
	LOW	MEDIUM	HIGH
1 well of a 6-well plate	350	700	1000
100 mm dish	2100	4200	6000
T-75 cm^2 flask	2800	5600	8000

7. Calculate the volume of cell aggregate mixture to plate (V_P) for each condition in your experiment:

$$V_P = \frac{N_P}{C}$$

8. Gently mix the cell aggregate mixture prior to plating to ensure a uniform suspension.
9. Add calculated volume of cell aggregate mixture (V_P) to coated wells containing TeSR™-E8™.
10. Continue with the appropriate passaging protocol (section 5.0).

Appendix 2: Flow Cytometry Protocols

Reagents and Materials

Antibodies

Antibodies can be used to characterize human ES and iPS cells by flow cytometry. The tables below contain information about a selection of antibodies available from STEMCELL Technologies that can be used to characterize human ES and iPS cells. For a complete list of antibodies, including other conjugates, sizes and clones, visit our website at www.stemcell.com/antibodies.

Surface Antigen Labeling

PRIMARY ANTIBODY*	SPECIES REACTIVITY	ISOTYPE	CATALOG #
Anti-Mouse SSEA-1 Antibody, Clone MC-480	Human, Mouse, Rat	IgM, kappa (Mouse)	60060
Anti-Mouse SSEA-3 Antibody, Clone MC-631	Human, Mouse, Rat, Rhesus	IgM, kappa (Rat)	60061
Anti-Human SSEA-4 Antibody, Clone MC-813-70	Human, Mouse, Rat, Rhesus, Cat, Chicken, Dog, Rabbit	IgG3, kappa (Mouse)	60062
Anti-Human SSEA-5 Antibody, Clone 8e11	Human	IgG1, kappa (Mouse)	60063
Anti-Human TRA-1-60 Antibody, Clone TRA-1-60R	Human, Rhesus, Rabbit	IgM, kappa (Mouse)	60064
Anti-Human TRA-1-81 Antibody, Clone TRA-1-81	Human, Rat, Rhesus	IgM, kappa (Mouse)	60065
Anti-Human TRA-2-49 Antibody, Clone TRA-2-49/6E	Human, Chimpanzee, Gibbon, Gorilla, Orangutan, Owl Monkey, Squirrel Monkey, Cat, Pig, Rabbit, Tiger	IgG1, kappa (Mouse)	60066
Anti-Human TRA-2-54 Antibody, Clone TRA-2-54/2J	Human, Chimpanzee, Gibbon, Gorilla, Orangutan, Owl Monkey, Squirrel Monkey, Cat, Pig, Rabbit, Tiger	IgG1, kappa (Mouse)	60067

*Optimal working dilutions of the antibodies should be determined by the end user.

Intracellular Antigen Labeling

PRIMARY ANTIBODY*	SPECIES REACTIVITY	ISOTYPE	CATALOG #
Anti-Human OCT4 (OCT3) Antibody, Clone 3A2A20	Human	IgG2b, kappa (Mouse)	60093

*Optimal working dilutions of the antibodies should be determined by the end user.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

General Reagents and Materials

REAGENTS AND MATERIALS	CATALOG #
D-PBS (Without Ca++ and Mg++)	37350
DMEM/F-12 with 15 mM HEPES	36254
Trypan Blue	07050
Gentle Cell Dissociation Reagent	07174
Dulbecco's Phosphate Buffered Saline with 2% Fetal Bovine Serum (2% FBS/PBS)	07905
1.7 mL microcentrifuge tubes	38038
5 mL round-bottom tubes	38007
15 mL conical tubes	38009
Propidium Iodide (optional for nuclear stain)	75002

Additional Reagents Required for Intracellular Antigen Labeling

Saponin Permeabilization Buffer (SPB)*

COMPONENT	CATALOG #	FINAL CONCENTRATION
Saponin	e.g. Fluka Biochemika 47036	1 mg/mL
10% BSA Solution	04915	1%
D-PBS (Without Ca++ and Mg++)	37350	to final volume

*Mix well and store at 2 - 8°C for up to 1 month.

2% Paraformaldehyde Solution*

COMPONENT	CATALOG #	FINAL CONCENTRATION
Paraformaldehyde	e.g. Affymetrix 19943 1 LT	2%
D-PBS (Without Ca++ and Mg++)	37350	to final volume

*Mix well and store at 2 - 8°C.

Preparation of a Single-Cell Suspension for Flow Cytometry

Prepare a single-cell suspension as indicated in section 7.2. Perform a viable cell count using Trypan Blue and a hemocytometer. The single-cell suspension may now be used for surface antigen and/or intracellular antigen labeling (see below for detailed protocols).

Surface Antigen Labeling Protocol

Note: Optimal concentrations of antibodies need to be predetermined by titration for each antibody.

1. Determine the number of samples required to perform flow cytometry including necessary labeling controls.
2. Aliquot approximately 1×10^5 cells per sample into a 5 mL round-bottom tube or a 1.7 mL microcentrifuge tube and place on ice.
3. Centrifuge cells at $300 \times g$ for 5 minutes.
4. While the samples are centrifuging, prepare a sufficient quantity of the primary antibody mix or the directly conjugated antibody mix (100 μ L/sample) using the appropriate antibody at the predetermined optimal working dilution.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

5. Carefully remove the supernatant without disrupting the cell pellet and resuspend cells in the primary antibody mix. Gently mix and incubate on ice for 15 - 60 minutes. If using a directly conjugated antibody, protect samples from exposure to direct light.
6. Add 1 mL of 2% FBS/PBS to each tube, gently mix and centrifuge at 300 x *g* for 5 minutes.
 - If using an unconjugated primary antibody: While the samples are centrifuging, prepare a sufficient quantity of the secondary antibody mix (100 μ L/sample) using the appropriate secondary antibody at the predetermined optimal working dilution. Proceed to step 7.
 - If using a directly conjugated antibody, proceed to step 9.
7. Carefully remove the supernatant without disturbing the cell pellet and resuspend the cells in the secondary antibody mix. Gently mix and incubate on ice for 15 - 60 minutes. Protect samples from exposure to direct light.
8. Add 1 mL of 2% FBS/PBS to each tube. Gently mix and centrifuge at 300 x *g* for 5 minutes.
9. Carefully remove the supernatant without disturbing the cell pellet and resuspend the cells in 200 - 300 μ L of 2% FBS/PBS. Transfer to a 5 mL round-bottom tube if necessary.

Optional nuclear stain: Propidium iodide (PI) can be added at a final concentration of 1 μ g/mL to assess viability (e.g. add 1 mg/mL PI at a 1 in 1000 dilution).
10. Place samples on ice, while avoiding exposure to direct light, and analyze by flow cytometry as soon as possible.

Intracellular Antigen Labeling Protocol for OCT3/OCT4

Note: Optimal concentrations of antibodies need to be predetermined by titration for each antibody.

1. Determine the number of samples required to perform flow cytometry including necessary labeling controls.
2. Aliquot approximately 4 - 8 x 10⁵ cells per sample into a 5 mL round-bottom tube or a 1.7 mL microcentrifuge tube.
3. Centrifuge cells at 300 x *g* for 5 minutes.
4. Carefully remove the supernatant without disrupting the cell pellet and resuspend cells in 250 μ L of 2% Paraformaldehyde Solution/tube. Gently mix and incubate on ice for 15 - 30 minutes.
5. Add 1 mL of 2% FBS/PBS per tube. Gently mix and centrifuge at 300 x *g* for 5 minutes.
6. Carefully remove the supernatant without disrupting the cell pellet and resuspend cells in 500 μ L of Saponin Permeabilization Buffer (SPB)/tube. Gently mix and incubate at room temperature (15 - 25°C) for 15 minutes.

Note: Cells should remain in SPB until the final resuspension step, prior to analysis by flow cytometry.

7. While the samples are incubating, prepare a sufficient quantity of the primary antibody mix (100 μ L/sample) at the predetermined optimal working dilution, using SPB as the diluent.
8. Centrifuge cells at 300 x *g* for 5 minutes.
9. Carefully remove the supernatant without disrupting the cell pellet and resuspend cells in the primary antibody mix (100 μ L/sample). Gently mix and incubate on ice for 15 - 60 minutes. If using a directly conjugated antibody, protect samples from exposure to direct light.

10. Add 1 mL of SPB to each tube. Gently mix and centrifuge at 300 x *g* for 5 minutes.
 - If using an unconjugated primary antibody: While the samples are centrifuging, prepare a sufficient quantity of the secondary antibody mix (100 µL/sample) using the appropriate secondary antibody at the predetermined optimal working dilution, using SPB as the diluent. Proceed to step 11.
 - If using a directly conjugated antibody, proceed to step 13.
11. Carefully remove the supernatant without disturbing the cell pellet and resuspend the cells in the secondary antibody mix. Gently mix and incubate on ice for 15 - 60 minutes. Protect samples from exposure to direct light.
12. Add 1 mL of SPB to each tube. Gently mix and centrifuge at 300 x *g* for 5 minutes.
13. Carefully remove the supernatant without disturbing the cell pellet and resuspend the cells in 300 µL of 2% FBS/PBS. Transfer to a 5 mL round-bottom tube if necessary.
14. Place samples on ice, while avoiding exposure to direct light, and analyze by flow cytometry as soon as possible.

Optional: To ensure that only single cells are assessed, examine a plot of FSC area versus FSC height in the linear range and gate out events that deviate from diagonal (see Figure 14).




Figure 14. Example of Doublet Discrimination by Flow Cytometry

Copyright © 2020 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, Scientists Helping Scientists, CellAdhere, FreSR, and ReLeSR are trademarks of STEMCELL Technologies Canada Inc. Corning and Matrigel are registered trademarks of Corning Incorporated. E8, mTeSR and TeSR are trademarks of WARF. Vitronectin XF is developed and manufactured by Nucleus Biologics, and Vitronectin XF is a trademark of Nucleus Biologics. CryoStor is a registered trademark of BioLife Solutions. Parafilm is a registered trademark of Bemis Company, Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

TECHNICAL MANUAL

Maintenance of Human Pluripotent Stem Cells in TeSR™-E8™



TOLL-FREE PHONE 1 800 667 0322

PHONE +1 604 877 0713

INFO@STEMCELL.COM

TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT WWW.STEMCELL.COM

DOCUMENT #10000005516 VERSION 03 JUL 2020 | FOR INTERNAL USE: MATERIAL #DX20809